EXAGEN INC (XGN)

US30068X1037 - Common Stock

3.39  -0.19 (-5.31%)

After market: 3.18 -0.21 (-6.19%)

Fundamental Rating

2

XGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of XGN have multiple concerns. While showing a medium growth rate, XGN is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XGN has reported negative net income.
In the past year XGN has reported a negative cash flow from operations.
In the past 5 years XGN always reported negative net income.
XGN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

XGN's Return On Assets of -38.82% is in line compared to the rest of the industry. XGN outperforms 58.20% of its industry peers.
Looking at the Return On Equity, with a value of -131.54%, XGN is doing worse than 62.16% of the companies in the same industry.
Industry RankSector Rank
ROA -38.82%
ROE -131.54%
ROIC N/A
ROA(3y)-39.45%
ROA(5y)-34.78%
ROE(3y)-82.51%
ROE(5y)-68.36%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

XGN's Gross Margin of 58.80% is fine compared to the rest of the industry. XGN outperforms 78.38% of its industry peers.
XGN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for XGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.54%
GM growth 5Y1.28%

More info and screens

2

2. Health

2.1 Basic Checks

XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
XGN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XGN has been increased compared to 5 years ago.
XGN has a worse debt/assets ratio than last year.

2.2 Solvency

XGN has an Altman-Z score of -7.31. This is a bad value and indicates that XGN is not financially healthy and even has some risk of bankruptcy.
XGN's Altman-Z score of -7.31 is on the low side compared to the rest of the industry. XGN is outperformed by 69.73% of its industry peers.
A Debt/Equity ratio of 1.54 is on the high side and indicates that XGN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.54, XGN is doing worse than 80.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z -7.31
ROIC/WACCN/A
WACC10.49%

2.3 Liquidity

XGN has a Current Ratio of 4.05. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.05, XGN is in line with its industry, outperforming 46.49% of the companies in the same industry.
XGN has a Quick Ratio of 4.05. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.05, XGN is in line with its industry, outperforming 48.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.05
Quick Ratio 4.05

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.46% over the past year.
Looking at the last year, XGN shows a small growth in Revenue. The Revenue has grown by 7.99% in the last year.
Measured over the past years, XGN shows a quite strong growth in Revenue. The Revenue has been growing by 10.13% on average per year.
EPS 1Y (TTM)49.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
Revenue 1Y (TTM)7.99%
Revenue growth 3Y7.77%
Revenue growth 5Y10.13%
Sales Q2Q%-6.78%

3.2 Future

Based on estimates for the next years, XGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.62% on average per year.
XGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.29% yearly.
EPS Next Y32.67%
EPS Next 2Y22.37%
EPS Next 3Y18.42%
EPS Next 5Y12.62%
Revenue Next Year10.39%
Revenue Next 2Y13.8%
Revenue Next 3Y13.62%
Revenue Next 5Y14.29%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XGN's earnings are expected to grow with 18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.37%
EPS Next 3Y18.42%

More info and screens

0

5. Dividend

5.1 Amount

XGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXAGEN INC

NASDAQ:XGN (1/6/2025, 8:09:29 PM)

After market: 3.18 -0.21 (-6.19%)

3.39

-0.19 (-5.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners47.52%
Inst Owner Change0%
Ins Owners9.04%
Ins Owner Change16.7%
Market Cap59.80M
Analysts82
Price Target6.8 (100.59%)
Short Float %0.84%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.24%
Min EPS beat(2)4.4%
Max EPS beat(2)54.08%
EPS beat(4)4
Avg EPS beat(4)33.91%
Min EPS beat(4)4.4%
Max EPS beat(4)54.08%
EPS beat(8)7
Avg EPS beat(8)28.93%
EPS beat(12)10
Avg EPS beat(12)20.9%
EPS beat(16)13
Avg EPS beat(16)19.19%
Revenue beat(2)1
Avg Revenue beat(2)2.42%
Min Revenue beat(2)-8.71%
Max Revenue beat(2)13.56%
Revenue beat(4)3
Avg Revenue beat(4)7.93%
Min Revenue beat(4)-8.71%
Max Revenue beat(4)17.87%
Revenue beat(8)7
Avg Revenue beat(8)19.18%
Revenue beat(12)10
Avg Revenue beat(12)15.42%
Revenue beat(16)13
Avg Revenue beat(16)13.25%
PT rev (1m)0%
PT rev (3m)6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.3%
EPS NY rev (1m)0%
EPS NY rev (3m)6.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.07
P/FCF N/A
P/OCF N/A
P/B 4.65
P/tB 4.65
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS3.16
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.82%
ROE -131.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.8%
FCFM N/A
ROA(3y)-39.45%
ROA(5y)-34.78%
ROE(3y)-82.51%
ROE(5y)-68.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.54%
GM growth 5Y1.28%
F-Score4
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.16%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.05
Quick Ratio 4.05
Altman-Z -7.31
F-Score4
WACC10.49%
ROIC/WACCN/A
Cap/Depr(3y)189.95%
Cap/Depr(5y)144.26%
Cap/Sales(3y)5.36%
Cap/Sales(5y)3.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
EPS Next Y32.67%
EPS Next 2Y22.37%
EPS Next 3Y18.42%
EPS Next 5Y12.62%
Revenue 1Y (TTM)7.99%
Revenue growth 3Y7.77%
Revenue growth 5Y10.13%
Sales Q2Q%-6.78%
Revenue Next Year10.39%
Revenue Next 2Y13.8%
Revenue Next 3Y13.62%
Revenue Next 5Y14.29%
EBIT growth 1Y42.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.28%
EBIT Next 3Y24.9%
EBIT Next 5Y15.78%
FCF growth 1Y84.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.69%
OCF growth 3YN/A
OCF growth 5YN/A